Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Trellus Health PLC ( (GB:TRLS) ) has provided an update.
Trellus Health has issued 5,538,461 new ordinary shares following the conversion of £27,000 of principal under its secured convertible loan notes, a move that modestly expands its equity base. The new shares are expected to be admitted to trading on AIM around 12 February 2026, taking the company’s total voting rights to 186,277,563 and providing an updated denominator for shareholders’ disclosure obligations under UK transparency rules.
The transaction reflects the ongoing utilisation of Trellus Health’s previously announced financing structure, with a small portion of debt transitioning into equity. While the amount raised is limited, the conversion reduces outstanding loan note principal and may incrementally strengthen the balance sheet, with implications for existing shareholders’ ownership percentages and for the company’s capital structure flexibility.
The most recent analyst rating on (GB:TRLS) stock is a Hold with a £0.74 price target. To see the full list of analyst forecasts on Trellus Health PLC stock, see the GB:TRLS Stock Forecast page.
Spark’s Take on GB:TRLS Stock
According to Spark, TipRanks’ AI Analyst, GB:TRLS is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, negative free cash flow, and declining equity—despite the benefit of having no debt. Technicals are the main positive, with strong momentum above major moving averages, but valuation remains constrained by loss-making results and no indicated dividend yield.
To see Spark’s full report on GB:TRLS stock, click here.
More about Trellus Health PLC
Trellus Health plc is a healthcare company listed on AIM that delivers Trellus Elevate, a digital, whole-person condition management platform integrating data analytics, resilience-based methodology, and expert coaching. The company initially targets chronic, high-cost gastrointestinal conditions such as inflammatory bowel disease, and also partners with pharmaceutical companies to support clinical trials and commercialisation.
Trellus Health’s value-based solutions aim to improve treatment adherence and emotional wellbeing for patients with complex chronic conditions, while reducing hospitalisations and emergency room visits. Founded by Mount Sinai experts in inflammatory bowel disease, the group positions itself as an innovator in technology-enhanced, resilience-focused chronic care with potential applicability across multiple long-term conditions.
Average Trading Volume: 2,354,273
Technical Sentiment Signal: Sell
Current Market Cap: £994.1K
Find detailed analytics on TRLS stock on TipRanks’ Stock Analysis page.